Protara Therapeutics, Inc. TARA

TARA Company Overview

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and cancer. The company’s pipeline is centered on immune-modulating and cell-based therapies intended to address conditions with limited treatment options and significant unmet medical need. Protara primarily operates within the biotechnology and oncology sectors, with a strategic emphasis on rare and specialty indications where regulatory pathways such as orphan drug designation may provide development and commercialization advantages.

The company’s principal programs include TARA-002, an investigational cell-based therapy being developed for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement therapy intended for patients receiving parenteral nutrition. Protara evolved from a series of biotechnology transactions and corporate restructurings, including the merger of Proteon Therapeutics, Inc. with ArTara Therapeutics, Inc., after which the combined company adopted the Protara Therapeutics name and shifted its strategic focus toward rare disease and oncology assets.